SUBSCRIBE
SUBSCRIBE
News   Policy

Sanofi-Aventis (France) Gets Non-Approvable Letter From US FDA For Dronedarone

August 31, 2006 | 
1 min read
PARIS, Aug 31 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) said on Thursday that U.S health authorities had rejected its application for dronedarone, a heart arrythmia treatment branded as Multaq.

>>> Discuss This Story

Regulatory Europe
Food and Drug Administration (FDA) Sanofi
MORE ON THIS TOPIC
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
June 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Handwriting check box on a blue background. Checklist and choice concept. Top view.
Approvals
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer
June 25, 2026
 · 
1 min read
 · 
Tristan Manalac
A gloved hand carefully collecting blood from a test tube while a microscope stands nearby, showcasing the intricate process of conducting lab blood tests for health analysis
Insights
Labs see rising demand for nitrosamine, topical performance and microbiome testing
June 25, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker